Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Wuhan Humanwell Acquires US Generic Drugmaker for $550 Million

publication date: Mar 30, 2016
Wuhan Humanwell Healthcare will acquire Epic Pharma, a New York state generic drug manufacturer, for $550 million. In a brief announcement, Humanwell said it would invest $270 million to create a US subsidiary, which would then own Epic. Formed in 2008, Epic bought a generic drug manufacturing previously owned by Sandoz. It produces a number of generic drugs and provides contract manufacturing services. In 2015, Epic said its revenues exceeded $120 million per year. More details....

Stock Symbol: (SHA: 600079)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital